Project Grant R01CA311924
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $820K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $833,467 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and deploy the ACTIVATE (AI-Driven Clinical Trial Information and Viability Assessment Tool for EHRs) platform. The project, which commenced September 17, 2025 and extends through June 30, 2030, will create open-source artificial intelligence tools designed to improve cancer...
- Federal Grant Award Summary Tufts Medical Center Parent, Inc. received a $3.28 million Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded on August 15, 2025, with performance extending through July 31, 2029. The grant funds development and deployment of English and Spanish-language Embodied Conversational Agents (ECAs) for cervical cancer screening abnormalities follow-up (ECA-CCSA). The smartphone-based ECAs will...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $817,829 Project Grant on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention designed to improve quality of life in lymphoma survivors during early post-treatment survivorship (0-2 years post-active treatment). The study will enroll 254...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded MGH Institute of Health Professions, Inc. a Project Grant totaling $696,498 (Award Date: May 1, 2026; Completion Date: April 30, 2031) under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention designed to improve functional recovery and participation in life activities among breast cancer survivors. The research will utilize the Multiphase Optimization Strategy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded New York University School of Medicine a $681,215 Project Grant effective September 1, 2025, through August 31, 2030, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award supports development of artificial intelligence (AI)-enabled point-of-care magnetic resonance (MR) imaging technology for clinically significant prostate cancer detection. The research addresses limitations of the...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $673,096 Project Grant on August 18, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to improve cancer and mental health care delivery for adults with serious mental illness (SMI). The award supports a multi-site cancer center network trial through July 31, 2030, implementing the BRIDGE Model—a person-centered collaborative care intervention that integrates proactive...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Maryland, College Park $5.67 million on August 15, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate an artificial intelligence-driven chatbot designed to increase human papillomavirus (HPV) vaccination rates among U.S. adolescents. The primary deliverable is a personalized AI chatbot that delivers evidence-based, tailored health communication to parents addressing...